EV148 first human RSV study
Eradivir’s RSV candidate EV148 uses antibody-recruiting small molecules. The pipeline targets first-in-human testing after planned late-2026 regulatory discussions.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Verify the jurisdiction and authorization path; planned discussions are not regulatory clearance or dosing.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Company target: early 2027 human studies; exact day unconfirmed
Company context
Opened official company release. The About Eradivir section explicitly calls Eradivir Inc. a privately held clinical-stage biotech company. Positive company self-report dated April 15, 2026; refresh before market activation, not an independent October registry audit.
Potential outcome market
Will the first participant receive EV148 in an authorized human RSV program by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.